Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway

Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway

The authors would like to note an omission of disclosure in this paper. Author JDS is cofounder, equity-holder, and consultant of GILTRx Therapeutics.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Investigational new drugs 2019-12, Vol.37 (6), p.1309-1309
Hauptverfasser: Zhao, Piming, Aguilar, Ana E., Lee, Joanna Y., Paul, Lucy A., Suh, Jung H., Puri, Latika, Zhang, Meng, Beckstead, Jennifer, Witkowski, Andrzej, Ryan, Robert O., Saba, Julie D.
Format: Artikel
Sprache:eng
Schlagworte:
AKT protein
Correction
Medicine
Medicine & Public Health
Neuroblastoma
Oncology
Pharmacology/Toxicology
Signal transduction
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The authors would like to note an omission of disclosure in this paper. Author JDS is cofounder, equity-holder, and consultant of GILTRx Therapeutics.
ISSN:0167-6997
1573-0646
DOI:10.1007/s10637-019-00772-w